These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 1283765)

  • 1. Lipoproteins, lipases, and the metabolic cardiovascular syndrome.
    Blomhoff JP
    J Cardiovasc Pharmacol; 1992; 20 Suppl 8():S22-5. PubMed ID: 1283765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbohydrate metabolism, insulin resistance, and metabolic cardiovascular syndrome.
    Vaaler S
    J Cardiovasc Pharmacol; 1992; 20 Suppl 8():S11-4. PubMed ID: 1283763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin resistance is independently associated with postprandial alterations of triglyceride-rich lipoproteins in type 2 diabetes mellitus.
    Annuzzi G; De Natale C; Iovine C; Patti L; Di Marino L; Coppola S; Del Prato S; Riccardi G; Rivellese AA
    Arterioscler Thromb Vasc Biol; 2004 Dec; 24(12):2397-402. PubMed ID: 15458975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exaggerated postprandial lipaemia and lower post-heparin lipoprotein lipase activity in middle-aged men.
    Jackson KG; Knapper-Francis JM; Morgan LM; Webb DH; Zampelas A; Williams CM
    Clin Sci (Lond); 2003 Oct; 105(4):457-66. PubMed ID: 12812518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pathologic decrease in lipoprotein lipase activity in relation to the development of hyperlipemias and their significance for coronary heart disease].
    Breier C
    Wien Klin Wochenschr Suppl; 1986; 167():1-16. PubMed ID: 3458343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of plasma free fatty acids on lipoprotein synthesis and diabetic dyslipidemia.
    Julius U
    Exp Clin Endocrinol Diabetes; 2003 Aug; 111(5):246-50. PubMed ID: 12951628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of triglyceride-rich lipoproteins to plasma free fatty acids.
    Miles JM; Nelson RH
    Horm Metab Res; 2007 Oct; 39(10):726-9. PubMed ID: 17952834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid and lipoprotein dysregulation in insulin resistant states.
    Avramoglu RK; Basciano H; Adeli K
    Clin Chim Acta; 2006 Jun; 368(1-2):1-19. PubMed ID: 16480697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin resistance in obesity as the underlying cause for the metabolic syndrome.
    Gallagher EJ; Leroith D; Karnieli E
    Mt Sinai J Med; 2010; 77(5):511-23. PubMed ID: 20960553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Are sports contraindicated in metabolic diseases?].
    Wirth A; Schettler G
    Med Klin; 1982 Jan; 77(3):25-38. PubMed ID: 7057728
    [No Abstract]   [Full Text] [Related]  

  • 11. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease.
    Reaven GM
    Panminerva Med; 2005 Dec; 47(4):201-10. PubMed ID: 16489319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skeletal muscle and nuclear hormone receptors: implications for cardiovascular and metabolic disease.
    Smith AG; Muscat GE
    Int J Biochem Cell Biol; 2005 Oct; 37(10):2047-63. PubMed ID: 15922648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Disorders of lipid metabolism in insulin resistance].
    Müller-Wieland D; Krone W
    Herz; 1995 Feb; 20(1):33-46. PubMed ID: 7713475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipoproteins abnormalities in obese insulin-resistant dogs.
    Bailhache E; Nguyen P; Krempf M; Siliart B; Magot T; Ouguerram K
    Metabolism; 2003 May; 52(5):559-64. PubMed ID: 12759884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathophysiologic changes in obesity.
    Angel A
    Can Med Assoc J; 1978 Dec; 119(12):1401-6. PubMed ID: 737617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The insulin resistance syndrome: mechanisms of clustering of cardiovascular risk.
    Chan JC; Tong PC; Critchley JA
    Semin Vasc Med; 2002 Feb; 2(1):45-57. PubMed ID: 16222595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease.
    Lara-Castro C; Fu Y; Chung BH; Garvey WT
    Curr Opin Lipidol; 2007 Jun; 18(3):263-70. PubMed ID: 17495599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Green tea extract impedes dyslipidaemia and development of cardiac dysfunction in streptozotocin-diabetic rats.
    Anandh Babu PV; Sabitha KE; Shyamaladevi CS
    Clin Exp Pharmacol Physiol; 2006 Dec; 33(12):1184-9. PubMed ID: 17184499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of lipases, lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in abnormal high density lipoprotein metabolism in insulin resistance and type 2 diabetes mellitus.
    de Vries R; Borggreve SE; Dullaart RP
    Clin Lab; 2003; 49(11-12):601-13. PubMed ID: 14651331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenic role of abnormal fatty acids and adipokines in the portal flow. Relevance for metabolic syndrome, hepatic steatosis and steatohepatitis.
    Brudaşcă I; Cucuianu M
    Rom J Intern Med; 2007; 45(2):149-57. PubMed ID: 18333368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.